HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 509: | Line 509: | ||
|[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]] | |[[HAEM5:Acute myeloid leukaemia with other defined genetic alterations|Acute myeloid leukaemia with other defined genetic alterations]] | ||
|Disease | |Disease | ||
|Samreen Mehak (trainee), Malini Sathanoori | |||
|3/2/2026 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 1,730: | Line 1,730: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||Sriharikrishnaa S | ||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | | 4/10/2026|| || Pending|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page. | ||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,740: | Line 1,740: | ||
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | |[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
|Disease | |Disease | ||
|Pallavi Khattar | |||
|3/2/2026 | |||
| | | | ||
| | |PENDING | ||
| | | | ||
|SG | |SG | ||
| Line 1,756: | Line 1,756: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
|Pallavi Khattar | |||
|3/2/2026 | |||
| | | | ||
| | |PENDING | ||
| | | | ||
|SG | |SG | ||
| | | | ||
|Email sent to request to update 2024 | |Email sent to request to update 2024. Sent e-mail to prev authors no reply. | ||
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | |(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia | ||
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | |(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI) | ||
| Line 1,772: | Line 1,772: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
|Pallavi Khattar | |||
|3/2/2026 | |||
| | | | ||
| | |PENDING | ||
| | | | ||
|SG | |SG | ||
| | | | ||
|Email sent to request to update 2024 | |Email sent to request to update 2024. Sent e-mail to prev authors no reply | ||
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) | ||
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | |Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG* | ||
| Line 1,934: | Line 1,934: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
|Sriharikrishnaa S | |||
|4/10/2026 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|SG | |SG | ||
| Line 2,793: | Line 2,793: | ||
!Prior Notes (4th Edition) | !Prior Notes (4th Edition) | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease|| | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Hayk Simonyan (trainee) and Ian King||3/16/2026 | ||
| | | | ||
| || ||SK|| ||prior authors not available | | || ||SK|| ||prior authors not available; Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author. | ||
|Angioimmunoblastic T-cell Lymphoma | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
| Line 2,802: | Line 2,802: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease|| | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Ian King||3/16/2026 | ||
| | | | ||
| || ||SK|| || | | || ||SK|| ||Rachel Burnside volunteered in 7/28/2023 but had to step back so found new author. | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,811: | Line 2,811: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||Ian King | ||
| || || || ||SK|| || | | 3/16/2026|| || || ||SK|| || | ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | ||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||